Surgical Outcome and Long-Term Survival of Conversion Surgery for Advanced Gastric Cancer.

Abstract

The present study aims to report the surgical outcome and long-term survival of conversion surgery and clarify its role in advanced gastric cancer. A total of 95 primary advanced gastric adenocarcinoma patients who underwent systemic chemotherapy and conversion surgery were reviewed retrospectively. The survival of conversion surgery was analyzed by Cox regression and the Kaplan-Meier method. Surgical outcomes were analyzed according to the Clavien-Dindo classification. The median survival time (MST) of the 95 patients was 26.8months, and the postoperative MST was 19.3months. The MSTs of the patients in categories 1, 2, 3, and 4 were 28.8, 25.5, 43.6, and 11.3months, respectively. The MSTs of the patients who underwent R0 resection (47 cases) and R1/2 resection (48 cases) were 49.3months and 21.9months, respectively. The MST of patients treated with total gastrectomy was shorter (21.9months) than that of patients who underwent proximal (55.0months) or distal (46.3months) gastrectomy. Patients who received more than 6 cycles of induction chemotherapy had a longer MST than patients who received 3-5 cycles or 1-2 cycles (MST: 55.0months versus 21.1months versus 21.7months). The incident postoperative complications and postoperative mortality rates were 10.5% and 1.1%, respectively. Advanced gastric cancer patients may obtain a survival benefit from conversion surgery, except category 4. Performing a sufficient number of cycles of induction chemotherapy (usually ≥ 6 cycles) is recommended. Surgical oncologists should perform R0 resection and avoid total gastrectomy.